Recent mixed-methods research highlights persistent gaps between the clinical management of IgA nephropathy (IgAN) and the patient experience. Based on 20 qualitative interviews and a survey of 106 patients, participants typically waited 1 to 2 years to reach a nephrologist after symptoms began, with hematuria and fatigue among the most commonly missed early signs. Although 80% identified symptom control and preservation of kidney function as top treatment priorities, only about half felt those goals were being met. The findings underscore how intermittent symptoms and delayed diagnostic evaluation can contribute to a prolonged path to biopsy-confirmed disease.
In practice, the patient perspective reinforces the importance of early recognition, clear communication, and timely referral as the IgAN treatment landscape expands. The research also identifies important treatment-access gaps: patients who present with more advanced kidney dysfunction may not meet eligibility criteria for newer therapies, while transplant recipients face concerns about disease recurrence with limited evidence to guide disease-modifying treatment. One patient and study co-author described progressing to transplantation after years of monitoring and emphasized the value of asking questions, finding trusted clinicians, building a support system, and preserving kidney function as early as possible.
Reference: Wade B. Diagnosis to Data: What Patient Experience Adds to IgAN Research. HCP Live. Published September 10, 2026. Accessed September 17, 2026. https://www.hcplive.com/view/diagnosis-to-data-what-patient-experience-adds-to-igan-research
Link: https://www.hcplive.com/view/diagnosis-to-data-what-patient-experience-adds-to-igan-research
